Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial Results
The foresiGHt trial met its primary efficacy endpoint by demonstrating superiority of lonapegsomatropin vs placebo with similar safety and tolerability, supporting its potential as a once-weekly treatment option for adults with GHD.
Institutions
- Jagiellonian University (PL)
- University of Alicante (ES)
- Barrow Neurological Institute (US)
- Mayo Clinic (US)
- Oregon Health & Science University (US)
- Washington University in St. Louis (US)
- WinnMed (US)
- University of Belgrade (RS)
- Massachusetts General Hospital (US)
- Kobe University Hospital (JP)
- VA Puget Sound Health Care System (US)
- Hospices Civils de Lyon (FR)
- Ascendis Pharma (Denmark) (DK)
- Nara Medical University (JP)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2025-12-19
- DOI
- https://doi.org/10.1210/clinem/dgaf680
- Citations
- 2
- Primary Topic
- Growth Hormone and Insulin-like Growth Factors
- Type
- article
- Field-Weighted Citation Impact
- 2.59